The results of our study are consistent with our prior published study that found that HER2‐positive breast cancer brain metastases exhibit a greater degree of enhancement on conventional contrast‐enhanced MR than HER2‐negative lesions [18]. This evidence concerns the gene ERBB2 and breast carcinoma.